|
|
Vol. 12.10 – 08 June, 2026
|
|
|
|
|
|
|
|
|
Single-cell RNA-sequencing and multiplex immunohistochemistry analyses demonstrated upregulated expression of inducible T cell co-stimulator ligand (ICOSLG) and RUNX1 in psoriatic keratinocytes. [Experimental & Molecular Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
DERMAL STEM CELLS & TISSUE REGENERATION
|
|
|
|
|
|
The authors activated the NLRP1 inflammasome in human keratinocytes cultivated in three-dimensional skin equivalents. NLRP1 activation induced histological and molecular features highly reminiscent of psoriasis.
[Cell Death & Disease]
|
|
|
|
|
|
Scientists investigated the protective role of microRNA-31-5p, which is elevated in vitiligo lesions, against UV-B-induced DNA damage in keratinocytes.
[Scientific Reports]
|
|
|
|
|
|
|
|
Investigators developed and assessed a physiologically relevant scaffold-free 3D melanoma model that mimics the morphological and functional features of the melanoma lesion.
[Biofabrication]
|
|
|
|
|
|
Scientists demonstrated for the first time that intravenous injection of melanoma-derived melanosomes into mice elicits protective B cell and antibody responses directed against the extracellular form of heat shock protein 70 (HSP70), a family of key regulators that promote self-signaling and proliferation of melanoma.
[Cell Reports]
|
|
|
|
|
|
Researchers observed a positive correlation between PHF20 expression and the malignancy and tumor grade of cutaneous squamous cell carcinoma. Functional studies suggest that PHF20 promotes oncogenic phenotypes, including proliferation, invasion, and epithelial-mesenchymal transition. [Cell Death & Disease]
|
|
|
|
|
|
|
|
The authors examine current evidence for adjuvant and neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma. [Journal for Immunotherapy of Cancer]
|
|
|
|
|
|
|
|
Vanda Pharmaceuticals Inc. announced that Japan’s Ministry of Health, Labour and Welfare has granted orphan drug designation to imsidolimab, a high‑affinity humanized immunoglobulin G4 monoclonal antibody, for the treatment of generalized pustular psoriasis. [Vanda Pharmaceuticals Inc.]
|
|
|
|
|
|
|
|
July 8-11, 2026 Montréal, Quebec, Canada
|
|
|
|
|
|
|
|
|
|
|
University of Arizona Cancer Center – Tucson, Arizona, United States
|
|
|
|
|
|
|
Imperial College London – London, England, United Kingdom
|
|
|
|
|
|
|
The University of Texas MD Anderson Cancer Center – Houston, Texas, United States
|
|
|
|
|
|
|
University of Virginia – Charlottesville, Virginia, United States
|
|
|
|
|
|
|
Heidelberg University – Heidelberg, Germany
|
|
|
|
|
|